Genetic and Adverse Health Outcome Associations with Treatment Resistant Hypertension in GenHAT
Table 3
Association of clinical outcomes with treatment resistant hypertension.
Clinical outcomes
African American
White
Number of events
Event rates per 1000 person-years
Odds ratio ( value) for cases versus controls
Number of events
Event rates per 1000 person-years
Odds ratio ( value) for cases versus controls
TRH cases ()
Controls ()
TRH cases
Controls
Unadjusted
Adjusted*
TRH cases ()
Controls ()
TRH cases
Controls
Unadjusted
Adjusted*
CHD (fatal CHD or nonfatal MI)
82
25
18.0
6.9
2.66 (<0.001)
3.44 (<0.001)
159
75
26.2
9.4
2.80 (<0.001)
2.40 (<0.001)
Stroke
43
22
9.3
6.1
1.55 (0.10)
1.15 (0.66)
64
27
10.3
3.4
3.04 (<0.001)
2.19 (0.003)
Heart failure
104
22
23.2
6.0
3.86 (<0.001)
2.69 (<0.001)
184
50
30.7
6.2
5.03 (<0.001)
3.98 (<0.001)
End-stage renal disease
28
0
6.0
0
23.1 (0.002)**
10.9 (0.03)**
20
4
3.2
0.5
6.33 (0.001)
3.89 (0.02)
All-cause death
103
51
20.7
13.5
1.48 (0.02)
1.66 (0.01)
127
88
19.1
10.6
1.69 (<0.001)
1.35 (0.06)
Combined CHD
142
50
32.5
13.9
2.36 (<0.001)
2.84 (<0.001)
307
175
54.6
22.6
2.44 (<0.001)
2.22 (<0.001)
Combined CVD
277
110
69.4
32.0
2.18 (<0.001)
2.11 (<0.001)
510
282
100.7
38.0
2.70 (<0.001)
2.42 (<0.001)
Adjusted for age, sex, randomized treatment group, baseline values of BMI, HDL, eGFR, SBP, and DBP, smoking status, diabetes status and history of LVH; **added 1 event into each case and control group to force estimate.
